<DOC>
	<DOCNO>NCT02970968</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study conduct United States . One hundred fifty ( 150 ) subject diagnose gastroparesis , satisfy selection criterion study , randomize one two treatment group , active placebo .</brief_summary>
	<brief_title>Study Assess Efficacy VLY-686 Relieving Symptoms Gastroparesis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study conduct United States . One hundred fifty ( 150 ) subject diagnose gastroparesis , satisfy selection criterion study , randomize one two treatment group , active placebo . The study divide two phase : screen phase evaluation phase . The screening phase include screen visit evaluate subject ' preliminary eligibility study . During screen phase , subject collect diary data least 4 week . The evaluation phase include 4 week randomize double-blind treatment .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>1 . Diagnosed gastroparesis ; 2 . Subjects must agree use contraception 3 . Ability acceptance provide write informed consent ; 4 . Willing participate pharmacogenomics sample collection ; 5 . Willing able comply study requirement restriction 6 . Willing participate interventional trial duration participation . 1 . Another active disorder treatment could explain contribute symptom opinion Investigator ( include limit gastric malignancy , neurological disorder , heavy dos strong anticholinergic ) ; 2 . Pregnancy nursing ; 3 . History intolerance and/or hypersensitivity medication similar VLY686 ( Tradipitant ) accompany excipients ; 4 . Use another NK1 antagonist palonosetronÍ¾ 5 . Exposure investigational medication , include placebo , within 60 day Baseline Visit ; 6 . Any reason determine Investigator may lead unfavorable riskbenefit study participation , may interfere study compliance , may confound study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>